Evidence map›Paper›PMID 41528560›Full record

ArticleJournal of gastrointestinal cancer2026

Outcomes of Ramucirumab Monotherapy for Advanced Gastric Cancer in a Multi-institutional Cohort Study in Japan.

Yoshinori Kikuchi, Sakae Nagaoka, Nobue Futawatari, Muneharu Fujisaki, Hidejiro Urakami, Mao Tsuru, Satoshi Yajima, Yoko Oshima, Hideaki Shimada

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yoshinori KikuchiDepartment of Clinical Oncology, Faculty of Medicine, Toho University, Ōta-ku, Tokyo, Japan. y-kikuchi@med.toho-u.ac.jp.
Sakae NagaokaDepartment of Gastroesophageal Surgery, Japanese Red Cross Medical Center, Shibuya-ku, Tokyo, Japan.
Nobue FutawatariDepartment of Surgery, Toho University Ohashi Medical Center, Meguro-ku, Tokyo, Japan.
Muneharu FujisakiDepartment of Surgery, Jikei University School of Medicine, Minato-ku, Tokyo, Japan.
Hidejiro UrakamiNational Hospital Organization Tokyo Medical Center, Meguro-ku, Tokyo, Japan.
Mao TsuruNTT Medical Center Tokyo, Shinagawa-ku, Tokyo, Japan.
Satoshi YajimaDivision of General and Gastroenterological Surgery, Department of Surgery (Omori), Toho University, Ōta-ku, Tokyo, Japan.
Yoko OshimaDivision of General and Gastroenterological Surgery, Department of Surgery (Omori), Toho University, Ōta-ku, Tokyo, Japan.
Hideaki ShimadaDivision of General and Gastroenterological Surgery, Department of Surgery (Omori), Toho University, Ōta-ku, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe REGARD trial resulted in insurance approval for ramucirumab monotherapy; however, it did not include Japanese patients. Subsequent phase II trials and retrospective studies have examined Japanese cohorts, but reports identifying prognostic factors remain limited.

methodsA total of 27 patients across six institutions received ramucirumab monotherapy as a second-line treatment for gastric cancer between September 2017 and December 2019.

resultsThe median age of 27 patients was 74 years (range: 36-90). Eighteen patients were male, and ten had intestinal-type gastric cancer. Metastases were observed in 6 patients in the liver, 3 in the lung, 18 in lymph nodes, and 14 in the peritoneum. Third-line chemotherapy was administered to 6 patients. The response rate was 3.7%, and the disease control rate was 18.5%. The median progression-free survival was 2.1 months, and the median overall survival was 3.0 months. Of the 27 patients, 6 received third-line treatment and 4 received nivolumab alone. Overall survival did not differ significantly between patients who received third-line treatment and those who did not. The median progression-free survival showed no significant differences based on tumor markers (carcinoembryonic antigen and CA19-9), age, histology, or metastases in the lung, lymph nodes, or peritoneum. In contrast, liver metastases were associated with poorer progression-free survival (HR:4.735 (95% CI: 1.508-14.86) and overall survival HR:2.906 (95% CI: 1.031-8.189).

conclusionsRamucirumab monotherapy is selected for patients with poor general condition, but it is suggested to have a poor prognosis, particularly in cases with liver metastases.

Indexed as

Antibodies, Monoclonal, HumanizedStomach NeoplasmsAdultAgedAged, 80 and overCohort StudiesFemaleHumansJapanMaleMiddle AgedPrognosisProgression-Free SurvivalRamucirumabRetrospective StudiesTreatment OutcomeAntibodies, Monoclonal, HumanizedRamucirumabGastric cancerLiver metastasisPerformance statusRamucirumab monotherapy

Identifiers

PMID41528560

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.